Previous studies have shown that the BCL is characterized by the loss of IKZF1 in the majority of the BCR/ABL1 positive ALL cases and loss of CDKN2A/B in approximately half of the CML/BCL patients [13]. This evidence concerns the gene CDKN2A and chronic myelogenous leukemia, BCR-ABL1 positive.